Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients

BACKGROUND: KEYNOTE‐063 (NCT03019588) investigated pembrolizumab versus paclitaxel as second‐line therapy in Asian patients with advanced programmed death ligand 1 (PD‐L1)–positive (combined positive score ≥1) gastric/gastroesophageal junction (GEJ) cancer. METHODS: This randomized, open‐label, phas...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Hyun Cheol, Kang, Yoon‐Koo, Chen, Zhendong, Bai, Yuxian, Wan Ishak, Wan Zamaniah, Shim, Byoung Yong, Park, Young Lee, Koo, Dong‐Hoe, Lu, Jianwei, Xu, Jianming, Chon, Hong Jae, Bai, Li‐Yuan, Zeng, Shan, Yuan, Ying, Chen, Yen‐Yang, Gu, Kangsheng, Zhong, Wen Yan, Kuang, Shu, Shih, Chie‐Schin, Qin, Shu‐Kui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299889/
https://www.ncbi.nlm.nih.gov/pubmed/34878659
http://dx.doi.org/10.1002/cncr.34019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299889/
https://www.ncbi.nlm.nih.gov/pubmed/34878659
http://dx.doi.org/10.1002/cncr.34019

Ejemplares similares